Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/11/2026 | $42.00 | Buy | Guggenheim |
| 3/25/2026 | $35.00 | Buy | BofA Securities |
| 1/29/2026 | $31.00 | Mkt Perform | Citizens JMP |
| 1/8/2026 | $28.00 | Buy | BTIG Research |
| 12/18/2025 | $18.00 | Neutral | Mizuho |
| 8/19/2025 | $36.00 | Overweight | Piper Sandler |
| 5/23/2025 | $8.00 | Underweight → Equal Weight | Wells Fargo |
| 4/17/2025 | $8.00 | Underweight | Wells Fargo |
4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on July 1, 2026 to four new employees under Bicara’s 2026 Inducement Plan as a material inducement to employment. The employees received, in the aggregate, non-qualified stock options to purchase 191,425 shares of Bicara’s common stock, par value $0.0001 per share, with an exercise price of $28.91 per share, equal to the closing price of Bicara’s common stock as reported by Nasdaq on July 1, 2026. One-fourth of the shares vest on th
At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care Phase 1b dataset of ~90 patients in 1L R/M HPV-negative HNSCC across all three doses demonstrated that deep responses translated into durable long-term outcomes across DOR, PFS, and OS, with a generally well-tolerated safety profile and no new safety signals Pooled analyses reinforced the TGF-β contribution and demonstrated that deep responders have greater durability of response and appeared more likely to remain progression-free and alive Company to h
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective May 8, 2026, it awarded an inducement grant to Christopher Sarchi under Bicara's 2026 Inducement Plan as a material inducement to his commencement of employment as Bicara's Chief Commercial Officer. Mr. Sarchi received a non-qualified stock option to purchase 282,240 shares of Bicara's common stock, par value $0.0001 per share, with an exercise price of $22.58 per share, equal to the closing price of Bicara's common stock as reported by Nasdaq on
Guggenheim initiated coverage of Bicara Therapeutics with a rating of Buy and set a new price target of $42.00
BofA Securities initiated coverage of Bicara Therapeutics with a rating of Buy and set a new price target of $35.00
Citizens JMP initiated coverage of Bicara Therapeutics with a rating of Mkt Perform and set a new price target of $31.00
4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
144 - Bicara Therapeutics Inc. (0002023658) (Subject)
8-K - Bicara Therapeutics Inc. (0002023658) (Filer)
144 - Bicara Therapeutics Inc. (0002023658) (Subject)
SC 13G - Bicara Therapeutics Inc. (0002023658) (Subject)
SC 13G - Bicara Therapeutics Inc. (0002023658) (Subject)
SC 13D - Bicara Therapeutics Inc. (0002023658) (Subject)
HOUSTON, July 31, 2025 /PRNewswire/ -- The Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of Rice University's health and medical technology discoveries into cures, announced today the appointment of Carolyn Ng to its external advisory board. A current business unit partner at TPG Life Sciences Innovations, Ng brings expertise in biotech and company building with a track record of guiding early to midstage companies across a wide range of therapeutic areas. "Carolyn's deep understanding of translational science, combined with her passion for fostering high-impact ventures, makes her an ideal addition to the board," said Omid Veiseh, professor of b
CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. "It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.
At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care Phase 1b dataset of ~90 patients in 1L R/M HPV-negative HNSCC across all three doses demonstrated that deep responses translated into durable long-term outcomes across DOR, PFS, and OS, with a generally well-tolerated safety profile and no new safety signals Pooled analyses reinforced the TGF-β contribution and demonstrated that deep responders have greater durability of response and appeared more likely to remain progression-free and alive Company to h
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report first quarter 2026 financial results and business updates before the market opens on Monday, May 11, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To access the live webcast,
BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report fourth quarter and full year 2025 financial results and business updates before the market opens on Monday, March 30, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To acces